Nasal Vaccine Delivery Route Protects Mice Against Multiple Lethal Flu Strains
Hitching a ride on a natural cellular transporter allows a conserved flu antigen to cross respiratory barriers and trigger long-lasting immunity.
Delivering a universal influenza vaccine through the nose by hitching a ride on a specialized cellular transporter successfully protected mice against multiple lethal strains of the virus, a study published in The Journal of clinical investigation indicates. Researchers engineered a novel fusion protein that targets the body’s natural molecular shuttle, known as the neonatal Fc receptor, to cross the respiratory lining and trigger powerful, long-lasting immunity in both the upper and lower airways.
How the Nasal Transporter Delivers Universal Vaccine Protection
Standard flu shots are typically injected into muscle or skin, which often fails to generate robust mucosal immunity right where respiratory viruses first attack. To overcome this hurdle, researchers led by scientists at the University of Maryland focused on the neonatal Fc receptor, a cellular gatekeeper normally responsible for transferring protective antibodies across epithelial barriers. By fusing a modified, stabilized hemagglutinin stalk antigen to a monomeric immunoglobulin G fragment, the team created a compound called Stalk-Fc that naturally binds to this receptor.
When administered intranasally to mice, the Stalk-Fc fusion protein efficiently traversed the polarized cells lining the nasal cavities. Control experiments using animals lacking the receptor or given an unmodified stalk protein showed that this transport mechanism is essential. Without the receptor carrying the antigen across the barrier, the vaccine candidate remained trapped on the surface and failed to elicit a meaningful immune response.

What Happens When Immunized Mice Face Lethal Influenza Strains
To test how broadly effective the strategy was, the team challenged the vaccinated mice with lethal doses of various group 1 influenza subtypes, including H1N1, rH5N1, and rH6N2, alongside a field strain of H9N2. While untreated control animals experienced severe weight loss of up to 25 percent and high mortality rates, mice receiving the Stalk-Fc treatment showed strong survival rates ranging from 80% to 91%.
Furthermore, analysis of tissue samples taken four days after infection revealed a notable 1.5 to 2.5 log reduction in live virus levels within the nasal turbinates and lungs of the vaccinated group. The treatment also stimulated the production of long-lived plasma cells in the bone marrow, maintaining detectable antibody levels in blood and respiratory secretions for up to 16 months post-immunization.
Understanding the Cellular Mechanisms Behind the Defense
The researchers evaluated the immune mechanisms responsible for the broad protection, identifying several distinct layers of defense. Vaccinated animals developed significant populations of tissue-resident memory T cells in their lungs, which are specialized immune cells that stay put to fight off future infections rapidly. Additional tests confirmed that even when circulating T cells were chemically sequestered, the lung-resident memory cells alone were enough to protect the mice from lethal H5N1 disease.

Beyond T cells, the immune sera generated by the nasal delivery exhibited strong neutralizing activity and effectively blocked viral membrane fusion. The antibodies also triggered Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity and phagocytosis, which actively clear virus-infected cells and neutralize pathogens across different group 1 strains.
Limitations and Next Steps for Human Application
Despite the strong results against group 1 influenza strains, the current formulation failed to protect against group 2 viruses like H3N2, reflecting structural differences in the stalk domains of different viral groups. The authors note that future vaccine designs will need to incorporate stalk antigens from group 2 and influenza B viruses, potentially combined with matrix protein 2, to create a truly universal multivalent mucosal vaccine suitable for humans.
The research was published in The Journal of clinical investigation on November 16, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Li, Weizhong., et al. “Mucosal vaccination with hemagglutinin stalk provides broad protection against influenza virus subtypes in mice.” Journal of Clinical Investigation, vol. 136, no. 22, November 16, 2026 American Society for Clinical Investigation, doi: 10.1172/JCI203675. <https://doi.org/10.1172/JCI203675>.
Cite this page:
- Posted by David Anderson